These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37671684)
1. Caveolin-3 loss linked with the P104L LGMD-1C mutation modulates skeletal muscle mTORC1 signalling and cholesterol homeostasis. Shah DS; Nisr RB; Krasteva-Christ G; Hundal HS J Cachexia Sarcopenia Muscle; 2023 Oct; 14(5):2310-2326. PubMed ID: 37671684 [TBL] [Abstract][Full Text] [Related]
2. Caveolin-3 deficiency associated with the dystrophy P104L mutation impairs skeletal muscle mitochondrial form and function. Shah DS; Nisr RB; Stretton C; Krasteva-Christ G; Hundal HS J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):838-858. PubMed ID: 32090499 [TBL] [Abstract][Full Text] [Related]
3. The caveolin-3 P104L mutation in LGMD-1C patients inhibits non-insulin-stimulated glucose metabolism and growth but promotes myocyte proliferation. Shang L; Chen T; Xian J; Deng Y; Huang Y; Zhao Q; Liang G; Liang Z; Lian F; Wei H; Huang Q Cell Biol Int; 2019 Jun; 43(6):669-677. PubMed ID: 30958599 [TBL] [Abstract][Full Text] [Related]
4. The Caveolin-3 P104L mutation of LGMD-1C leads to disordered glucose metabolism in muscle cells. Deng YF; Huang YY; Lu WS; Huang YH; Xian J; Wei HQ; Huang Q Biochem Biophys Res Commun; 2017 Apr; 486(2):218-223. PubMed ID: 28232187 [TBL] [Abstract][Full Text] [Related]
5. Expression of the muscular dystrophy-associated caveolin-3(P104L) mutant in adult mouse skeletal muscle specifically alters the Ca(2+) channel function of the dihydropyridine receptor. Weiss N; Couchoux H; Legrand C; Berthier C; Allard B; Jacquemond V Pflugers Arch; 2008 Nov; 457(2):361-75. PubMed ID: 18509671 [TBL] [Abstract][Full Text] [Related]
6. Loss of caveolin-3 induced by the dystrophy-associated P104L mutation impairs L-type calcium channel function in mouse skeletal muscle cells. Couchoux H; Allard B; Legrand C; Jacquemond V; Berthier C J Physiol; 2007 May; 580(Pt.3):745-54. PubMed ID: 17317753 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex. Galbiati F; Volonte D; Minetti C; Chu JB; Lisanti MP J Biol Chem; 1999 Sep; 274(36):25632-41. PubMed ID: 10464299 [TBL] [Abstract][Full Text] [Related]
8. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3. Galbiati F; Volonte D; Minetti C; Bregman DB; Lisanti MP J Biol Chem; 2000 Dec; 275(48):37702-11. PubMed ID: 10973975 [TBL] [Abstract][Full Text] [Related]
9. Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C. Volonte D; Peoples AJ; Galbiati F Mol Biol Cell; 2003 Oct; 14(10):4075-88. PubMed ID: 14517320 [TBL] [Abstract][Full Text] [Related]
10. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. Smythe GM; Eby JC; Disatnik MH; Rando TA J Cell Sci; 2003 Dec; 116(Pt 23):4739-49. PubMed ID: 14600260 [TBL] [Abstract][Full Text] [Related]
11. An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy. Ohsawa Y; Okada T; Nishimatsu S; Ishizaki M; Suga T; Fujino M; Murakami T; Uchino M; Tsuchida K; Noji S; Hinohara A; Shimizu T; Shimizu K; Sunada Y Lab Invest; 2012 Aug; 92(8):1100-14. PubMed ID: 22584670 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. Sotgia F; Woodman SE; Bonuccelli G; Capozza F; Minetti C; Scherer PE; Lisanti MP Am J Physiol Cell Physiol; 2003 Nov; 285(5):C1150-60. PubMed ID: 12839838 [TBL] [Abstract][Full Text] [Related]
13. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. Galbiati F; Engelman JA; Volonte D; Zhang XL; Minetti C; Li M; Hou H; Kneitz B; Edelmann W; Lisanti MP J Biol Chem; 2001 Jun; 276(24):21425-33. PubMed ID: 11259414 [TBL] [Abstract][Full Text] [Related]
14. Caveolin-3 associates with and affects the function of hyperpolarization-activated cyclic nucleotide-gated channel 4. Ye B; Balijepalli RC; Foell JD; Kroboth S; Ye Q; Luo YH; Shi NQ Biochemistry; 2008 Nov; 47(47):12312-8. PubMed ID: 19238754 [TBL] [Abstract][Full Text] [Related]
15. A CAV3 microdeletion differentially affects skeletal muscle and myocardium. Cagliani R; Bresolin N; Prelle A; Gallanti A; Fortunato F; Sironi M; Ciscato P; Fagiolari G; Bonato S; Galbiati S; Corti S; Lamperti C; Moggio M; Comi GP Neurology; 2003 Dec; 61(11):1513-9. PubMed ID: 14663034 [TBL] [Abstract][Full Text] [Related]
16. Biochemical and pathological changes result from mutated Caveolin-3 in muscle. González Coraspe JA; Weis J; Anderson ME; Münchberg U; Lorenz K; Buchkremer S; Carr S; Zahedi RP; Brauers E; Michels H; Sunada Y; Lochmüller H; Campbell KP; Freier E; Hathazi D; Roos A Skelet Muscle; 2018 Aug; 8(1):28. PubMed ID: 30153853 [TBL] [Abstract][Full Text] [Related]
17. Activation of eIF4E-binding-protein-1 rescues mTORC1-induced sarcopenia by expanding lysosomal degradation capacity. Crombie EM; Kim S; Adamson S; Dong H; Lu TC; Wu Y; Wu Y; Levy Y; Stimple N; Lam WMR; Hey HWD; Withers DJ; Hsu AL; Bay BH; Ochala J; Tsai SY J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):198-213. PubMed ID: 36398408 [TBL] [Abstract][Full Text] [Related]
18. Two novel CAV3 gene mutations in Japanese families. Sugie K; Murayama K; Noguchi S; Murakami N; Mochizuki M; Hayashi YK; Nonaka I; Nishino I Neuromuscul Disord; 2004 Dec; 14(12):810-4. PubMed ID: 15564037 [TBL] [Abstract][Full Text] [Related]
19. Caveolin-3 is a direct molecular partner of the Cav1.1 subunit of the skeletal muscle L-type calcium channel. Couchoux H; Bichraoui H; Chouabe C; Altafaj X; Bonvallet R; Allard B; Ronjat M; Berthier C Int J Biochem Cell Biol; 2011 May; 43(5):713-20. PubMed ID: 21262376 [TBL] [Abstract][Full Text] [Related]
20. Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation. Merrick D; Stadler LK; Larner D; Smith J Dis Model Mech; 2009; 2(7-8):374-88. PubMed ID: 19535499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]